Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MINIRIN is a nasal spray formulation of desmopressin (DDAVP), a synthetic vasopressin analog approved in 2002. It is indicated for diabetes insipidus, nocturnal enuresis, and hemophilia A/von Willebrand disease. The drug works by replacing or mimicking antidiuretic hormone (ADH) to regulate water reabsorption in the kidneys.
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect consolidation of commercial teams and shift toward defensive strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
Study of Minirin Melt® in Adult Patients With Nocturia
A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia
A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
Worked on MINIRIN at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MINIRIN offers stability in a mature market but limited growth opportunity; roles focus on defending market share, managing payer relationships, and transitioning to generic/biosimilar strategies. Career advancement may be constrained by product lifecycle stage and limited clinical expansion activity.